First Patient Dosed in QBiotics MSD Clinical Trial Collaboration for Unresectable Melanoma
- Written by PR Newswire
- First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA)
- The Phase Ib/IIa study will test the safety, optimal dose and tumour response of the combination in patients with...